Phase 3 Atrial Fibrillation Trial, Recruiting NCT05928728 Sponsor: Herlev and Gentofte Hospital Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 3 Atrial Fibrillation Trial, Recruiting

NCT05928728
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You live in the Capital Region of Denmark
  • You are over 18 years old
  • You have been diagnosed with atrial fibrillation (AF) that comes and goes or is ongoing (not permanent)
  • You have had or are scheduled for a cardioversion procedure (a procedure to reset your heart rhythm) that was successful
  • If you are a woman who could become pregnant, you are using an accepted form of contraception throughout the study and for 30 days after it ends (such as the pill, implant, injection, patch, vaginal ring, or an IUD); or you are past menopause or have had a procedure making pregnancy impossible
  • You are willing and able to give written consent and follow the study requirements
  • You are receiving the appropriate treatments for your atrial fibrillation and any related conditions, as judged by the study doctor

Who may not be able to join:

  • You are already taking colchicine (the study drug) for another condition, such as gout
  • You have a known allergy or bad reaction to colchicine
  • Your blood pressure is very high and not controlled (confirm with trial site)
  • You have had cancer of any type, except for certain successfully treated skin cancers, localised prostate cancer, or localised cervical changes (confirm with trial site)
  • You have serious liver disease, such as cirrhosis or chronic active hepatitis
  • You are on kidney dialysis (haemodialysis)
  • Your kidneys are not working well enough, based on a blood test measuring kidney function (confirm with trial site)
  • You are taking certain medications that could interfere with how colchicine works in your body (confirm with trial site for the specific list)
  • You have permanent atrial fibrillation (where the heart is always out of rhythm)
  • You are pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months of finishing it
  • You have had significant problems with drug or alcohol use in the past year
  • You are currently taking or planning to take long-term steroid tablets or injections during the study (steroid creams or inhalers are allowed)
  • You are planning to have an ablation procedure (a procedure using heat or cold to correct heart rhythm) as a treatment for AF
  • You have had heart surgery or an ablation procedure in the last three months
  • You have a chronic bowel condition such as Crohn's disease or ulcerative colitis, or you have ongoing long-term diarrhoea
  • You have taken part in another clinical trial or used another experimental treatment within the last 30 days
  • You have another medical or surgical condition that the study doctor feels could put you at risk or prevent you from completing the study
  • Your heart is still in an abnormal rhythm (AF) at the time you would be enrolled in the study, confirmed by a heart tracing (ECG)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Adam Femerling Langhoff, M.D., Herlev and Gentofte Hospital

Phone: +4522552317

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Herlev and Gentofte Hospital
Registry
ClinicalTrials.gov
Start date
3 July 2023
Est. completion
14 June 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Between-group difference in change in time to first AF admission measured in days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov